Eli Lilly is aggressively broadening its cancer portfolio by purchasing Loxo Oncology for $8 billion! Loxo shareholders are having a field day with 85% premium on share price. Despite the expensive deal value, the purchase is highly appreciated due to Loxo's hitherto success in cancer treatment drugs.
a 60+% premium? https://www.marketwatch.com/story/lilly-to-buy-loxo-oncology-in-a-8-billion-deal-for-a-68-premium-2019-01-07 So easy to spend money like this, but who will pay the price?
Lilly has to buy innovation to stay relevant since its own internal teams can't produce squat. Just take the annual payroll of Lilly's research teams times years of unproductive research. It adds up to a lot more than $8 billion. If I were CEO, I would CAN all the Lilly research teams and just buy innovative solutions from others.
Lilly can their research many years ago. It went to China remember and how did that work it. For who’s going to pay for this well it will be on the backs of those who get let go that who.
colossal incompetence. Can the six sigma. Get the party started. No researcher can be productive as a corporate drone.
